Targeting the Androgen Receptor in Breast Cancer
- KeeMing Chia,
- Megan O’Brien,
- Myles Brown,
- Elgene Lim
- … show all 4 hide
Rent the article at a discount
Rent now* Final gross prices may vary according to local VAT.
Get AccessAbstract
The androgen receptor (AR) is expressed in the majority of breast cancer and across the three main breast cancer subtypes. Historically, the oncogenic role of AR has best been described in molecular apocrine breast cancers, an estrogen receptor (ER)−/AR+ subtype which has a steroid response signature similar to that in the ER-positive breast cancer. The signalling effect of AR is likely to be different across breast cancer subtypes, and particularly important is its interaction with ER signalling. Despite the high frequency of AR expression in breast cancer, it is still not a standard clinical practice to use AR antagonists as therapy. Older trials of AR-directed therapies in breast cancer have had generally been disappointing. More recently, more potent, next-generation, AR-directed therapies have been developed in the context of prostate cancer. Here, we will review the emerging literature dissecting the role of AR signalling in a context-dependent manner in breast cancer and the renewed interest and wave of clinical trials targeting the AR in breast cancer.
- Park, S, Koo, JS, Kim, MS, Park, HS, Lee, JS, Lee, JS (2011) Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol: Off J Eur Soc Med Oncol / ESMO 22: pp. 1755-62 CrossRef
- Niemeier, LA, Dabbs, DJ, Beriwal, S, Striebel, JM, Bhargava, R (2010) Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol : Off J U S Can Acad Pathol Inc 23: pp. 205-12 CrossRef
- Qi, JP, Yang, YL, Zhu, H, Wang, J, Jia, Y, Liu, N (2012) Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients. Breast Cancer : Basic Clin Research 6: pp. 1-8
- Ni, M, Chen, Y, Lim, E, Wimberly, H, Bailey, ST, Imai, Y (2011) Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 20: pp. 119-31 CrossRef
- Lehmann, BD, Bauer, JA, Chen, X, Sanders, ME, Chakravarthy, AB, Shyr, Y (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: pp. 2750-67 CrossRef
- Safarpour, D, Pakneshan, S, Tavassoli, FA (2014) Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?. Am J Cancer Res 4: pp. 353-68
- Micello, D, Marando, A, Sahnane, N, Riva, C, Capella, C, Sessa, F (2010) Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers. Virchows Archiv : Int J Pathol 457: pp. 467-76 CrossRef
- A.M.A. Androgens and estrogens in the treatment of disseminated mammary carcinoma - Retrospective study of 944 patients. JAMA 172: pp. 1271-83 CrossRef
- Jordan, VC, Robinson, SP (1987) Species-specific pharmacology of antiestrogens: role of metabolism. Fed Proc 46: pp. 1870-4
- Goldenberg, IS (1964) Testosterone propionate therapy in breast cancer. JAMA 188: pp. 1069-72 CrossRef
- Boni, C, Pagano, M, Panebianco, M, Bologna, A, Sierra, NM, Gnoni, R (2014) Therapeutic activity of testoterone in metastatic breast cancer. Anticancer Res 34: pp. 1287-90
- Ingle, JN, Twito, DI, Schaid, DJ, Cullinan, SA, Krook, JE, Mailliard, JA (1991) Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer 67: pp. 886-91 CrossRef
- Gordan, GS, Halden, A, Horn, Y, Fuery, JJ, Parsons, RJ, Walter, RM (1973) Calusterone (7beta,17alpha-dimethyltestosterone) as primary and secondary therapy of advanced breast cancer. Oncology 28: pp. 138-46 CrossRef
- Dobs, AS, Boccia, RV, Croot, CC, Gabrail, NY, Dalton, JT, Hancock, ML (2013) Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol 14: pp. 335-45 CrossRef
- Perrault, DJ, Logan, DM, Stewart, DJ, Bramwell, VH, Paterson, AH, Eisenhauer, EA (1988) Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. Investig New Drugs 6: pp. 207-10 CrossRef
- Millward, MJ, Cantwell, BM, Dowsett, M, Carmichael, J, Harris, AL (1991) Phase II clinical and endocrine study of Anandron (RU-23908) in advanced post-menopausal breast cancer. Br J Cancer 63: pp. 763-4 CrossRef
- Gucalp, A, Tolaney, S, Isakoff, SJ, Ingle, JN, Liu, MC, Carey, LA (2013) Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res: Off J Am Assoc Cancer R 19: pp. 5505-12 CrossRef
- Tran, C, Ouk, S, Clegg, NJ, Chen, Y, Watson, PA, Arora, V (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (New York, NY) 324: pp. 787-90 CrossRef
- Clegg, NJ, Wongvipat, J, Joseph, JD, Tran, C, Ouk, S, Dilhas, A (2012) ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 72: pp. 1494-503 CrossRef
- Wong, YN, Ferraldeschi, R, Attard, G, Bono, J (2014) Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nat Rev Clin Oncol 11: pp. 365-76 CrossRef
- Peters, AA, Buchanan, G, Ricciardelli, C, Bianco-Miotto, T, Centenera, MM, Harris, JM (2009) Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 69: pp. 6131-40 CrossRef
- Lanzino, M, Amicis, F, McPhaul, MJ, Marsico, S, Panno, ML, Ando, S (2005) Endogenous coactivator ARA70 interacts with estrogen receptor alpha (ERalpha) and modulates the functional ERalpha/androgen receptor interplay in MCF-7 cells. J Biol Chem 280: pp. 20421-30 CrossRef
- Hu, R, Dawood, S, Holmes, MD, Collins, LC, Schnitt, SJ, Cole, K (2011) Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res: Off J Am Assoc Cancer Res 17: pp. 1867-74 CrossRef
- Castellano, I, Allia, E, Accortanzo, V, Vandone, AM, Chiusa, L, Arisio, R (2010) Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat 124: pp. 607-17 CrossRef
- Gonzalez-Angulo, AM, Stemke-Hale, K, Palla, SL, Carey, M, Agarwal, R, Meric-Berstam, F (2009) Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res : Off J Am Assoc Cancer Res 15: pp. 2472-8 CrossRef
- Amicis, F, Thirugnansampanthan, J, Cui, Y, Selever, J, Beyer, A, Parra, I (2010) Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat 121: pp. 1-11 CrossRef
- Cops, EJ, Bianco-Miotto, T, Moore, NL, Clarke, CL, Birrell, SN, Butler, LM (2008) Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. J Steroid Biochem Mol Biol 110: pp. 236-43 CrossRef
- Rizza, P, Barone, I, Zito, D, Giordano, F, Lanzino, M, Amicis, F (2014) Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines. Breast Cancer Res: BCR 16: pp. R21 CrossRef
- Vera-Badillo, FE, Templeton, AJ, Gouveia, P, Diaz-Padilla, I, Bedard, PL, Al-Mubarak, M (2014) Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst 106: pp. djt319 CrossRef
- Park, S, Park, HS, Koo, JS, Yang, WI, Kim, SI, Park, BW (2012) Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers. Breast Cancer Res Treat 133: pp. 311-20 CrossRef
- Nakopoulou, L, Lazaris, AC, Panayotopoulou, EG, Giannopoulou, I, Givalos, N, Markaki, S (2004) The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol 57: pp. 523-8 CrossRef
- Strom, A, Hartman, J, Foster, JS, Kietz, S, Wimalasena, J, Gustafsson, JA (2004) Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci U S A 101: pp. 1566-71 CrossRef
- Omoto, Y, Eguchi, H, Yamamoto-Yamaguchi, Y, Hayashi, S (2003) Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene 22: pp. 5011-20 CrossRef
- Grober, OM, Mutarelli, M, Giurato, G, Ravo, M, Cicatiello, L, Filippo, MR (2011) Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation. BMC Genomics 12: pp. 36 CrossRef
- Macedo, LF, Guo, Z, Tilghman, SL, Sabnis, GJ, Qiu, Y, Brodie, A (2006) Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res 66: pp. 7775-82 CrossRef
- Chanplakorn, N, Chanplakorn, P, Suzuki, T, Ono, K, Wang, L, Chan, MS (2011) Increased 5alpha-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation. Horm Cancer 2: pp. 73-81 CrossRef
- Cochrane, DR, Bernales, S, Jacobsen, BM, Cittelly, DM, Howe, EN, D’Amato, NC (2014) Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res : BCR 16: pp. R7 CrossRef
- Massarweh, S, Osborne, CK, Creighton, CJ, Qin, L, Tsimelzon, A, Huang, S (2008) Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68: pp. 826-33 CrossRef
- Loh, YN, Hedditch, EL, Baker, LA, Jary, E, Ward, RL, Ford, CE (2013) The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. BMC Cancer 13: pp. 174 CrossRef
- Huang, R, Faratian, D, Sims, AH, Wilson, D, Thomas, JS, Harrison, DJ (2014) Increased STAT1 signaling in endocrine-resistant breast cancer. PLoS One 9: pp. e94226 CrossRef
- Morrison, G, Fu, X, Shea, M, Nanda, S, Giuliano, M, Wang, T (2014) Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance. Breast Cancer Res Treat 144: pp. 263-72 CrossRef
- Tilghman, SL, Townley, I, Zhong, Q, Carriere, PP, Zou, J, Llopis, SD (2013) Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness. Mol Cell Proteomics : MCP 12: pp. 2440-55 CrossRef
- Vilquin, P, Villedieu, M, Grisard, E, Ben Larbi, S, Ghayad, SE, Heudel, PE (2013) Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor. Int J Cancer J Int du Cancer 133: pp. 1589-602 CrossRef
- Farmer, P, Bonnefoi, H, Becette, V, Tubiana-Hulin, M, Fumoleau, P, Larsimont, D (2005) Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24: pp. 4660-71 CrossRef
- Robinson, JL, Macarthur, S, Ross-Innes, CS, Tilley, WD, Neal, DE, Mills, IG (2011) Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J 30: pp. 3019-27 CrossRef
- Chia, KM, Liu, J, Francis, GD, Naderi, A (2011) A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. Neoplasia (New York, NY) 13: pp. 154-66
- Ni, M, Chen, Y, Fei, T, Li, D, Lim, E, Liu, XS (2013) Amplitude modulation of androgen signaling by c-MYC. Genes Dev 27: pp. 734-48 CrossRef
- Naderi, A, Chia, KM, Liu, J (2011) Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. Breast Cancer Res: BCR 13: pp. R36 CrossRef
- Lehmann, BD, Bauer, JA, Schafer, JM, Pendleton, CS, Tang, L, Johnson, KC (2014) PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res: BCR 16: pp. 406 CrossRef
- Cuenca-Lopez, MD, Montero, JC, Morales, JC, Prat, A, Pandiella, A, Ocana, A (2014) Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer 14: pp. 302 CrossRef
- Title
- Targeting the Androgen Receptor in Breast Cancer
- Journal
-
Current Oncology Reports
17:4
- Online Date
- February 2015
- DOI
- 10.1007/s11912-014-0427-8
- Print ISSN
- 1523-3790
- Online ISSN
- 1534-6269
- Publisher
- Springer US
- Additional Links
- Topics
- Keywords
-
- Androgen receptor
- Breast cancer
- Breast cancer subtype
- Androgen receptor-directed therapy
- Industry Sectors
- Authors
-
- KeeMing Chia (1)
- Megan O’Brien (1)
- Myles Brown (4) (5)
- Elgene Lim (1) (2) (3) (4) (5)
- Author Affiliations
-
- 1. Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
- 4. Dana-Farber Cancer Institute, Boston, MA, USA
- 5. Harvard University, Boston, MA, USA
- 2. University of Melbourne, Melbourne, Victoria, Australia
- 3. Latrobe University, Bundoora, Victoria, Australia
-